PRMT6介导的CRAF甲基化通过ERK依赖的PKM2核转位调控有氧糖酵解驱动的肝癌发生
该研究利用功能获得与缺失的体外实验(患者来源类器官和细胞培养)及体内PET-MRI动物模型,发现PRMT6通过将CRAF精氨酸100位甲基化,干扰其RAS/RAF结合,改变ERK介导的PKM2核转位,从而调控肝细胞癌有氧糖酵解。PRMT6-ERK-PKM2轴在PRMT6敲除小鼠模型和临床样本中得以确认,PRMT6受缺氧诱导并经REST转录抑制,2-脱氧葡萄糖可逆转PRMT6缺失介导的致瘤性和索拉非尼耐药。
要点
- PRMT6通过甲基化CRAF R100抑制RAS/RAF结合,影响ERK依赖的PKM2核转位。
- PRMT6-ERK-PKM2轴在HCC小鼠模型和临床样本中得到验证。
- 2-脱氧葡萄糖可逆转PRMT6缺失介导的致瘤性和索拉非尼耐药。
核心结论
- PRMT6-ERK-PKM2调控轴是肿瘤细胞Warburg效应的重要决定因素,并提供了致瘤性、索拉非尼耐药与葡萄糖代谢之间的机制联系。
研究设计与样本
- 研究采用功能获得与缺失的体外研究(患者来源类器官和细胞培养)以及体内PET-MRI动物模型。
主要发现
- PRMT6将CRAF精氨酸100位甲基化,干扰其RAS/RAF结合潜力,从而改变ERK介导的PKM2向细胞核转位。
- PRMT6-ERK-PKM2信号轴在PRMT6内源性敲除的HCC小鼠模型及HCC临床样本中得到确认。
- PRMT6被鉴定为缺氧的靶点,通过转录抑制因子REST介导,将PRMT6与缺氧驱动糖酵解事件联系起来。
- 2-脱氧葡萄糖(糖酵解抑制剂)可逆转PRMT6缺失介导的致瘤性和索拉非尼耐药。
临床怎么用
- PRMT6-ERK-PKM2轴可能作为HCC糖酵解和索拉非尼耐药的潜在干预靶点。
- 糖酵解抑制剂2-脱氧葡萄糖在PRMT6缺陷的HCC中显示出逆转致瘤性和索拉非尼耐药的治疗潜力。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Most tumor cells use aerobic glycolysis (the Warburg effect) to support anabolic growth and promote tumorigenicity and drug resistance. Intriguingly, the molecular mechanisms underlying this phenomenon are not well understood. In this work, using gain-of-function and loss-of-function in vitro studies in patient-derived organoid and cell cultures as well as in vivo positron emission tomography-magnetic resonance imaging animal models, we showed that protein arginine N-methyltransferase 6 (PRMT6) regulates aerobic glycolysis in human hepatocellular carcinoma (HCC) through nuclear relocalization of pyruvate kinase M2 isoform (PKM2), a key regulator of the Warburg effect. APPROACH AND RESULTS: We found PRMT6 to methylate CRAF at arginine 100, interfering with its RAS/RAF binding potential, and therefore altering extracellular signal-regulated kinase (ERK)-mediated PKM2 translocation into the nucleus. This altered PRMT6-ERK-PKM2 signaling axis was further confirmed in both a HCC mouse model with endogenous knockout of PRMT6 as well as in HCC clinical samples. We also identified PRMT6 as a target of hypoxia through the transcriptional repressor element 1-silencing transcription factor, linking PRMT6 with hypoxia in driving glycolytic events. Finally, we showed as a proof of concept the therapeutic potential of using 2-deoxyglucose, a glycolysis inhibitor, to reverse tumorigenicity and sorafenib resistance mediated by PRMT6 deficiency in HCC. CONCLUSIONS: Our findings indicate that the PRMT6-ERK-PKM2 regulatory axis is an important determinant of the Warburg effect in tumor cells, and provide a mechanistic link among tumorigenicity, sorafenib resistance, and glucose metabolism.
引用
- Wong TL, Ng KY, Tan KV, et al. CRAF Methylation by PRMT6 Regulates Aerobic Glycolysis-Driven Hepatocarcinogenesis via ERK-Dependent PKM2 Nuclear Relocalization and Activation. Hepatology. 2020. PMID: 31469916. doi:10.1002/hep.30923
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。